

The Company: **Gi Group Poland S.A.**

Current report No.: **70 /2021**

Date: **16 December 2021**

Time: **06:15 p.m.**

Subject: **Making public of delayed confidential information concerning establishment of preliminary terms of sale of share in Prohumán 2004 Kft.**

Pursuant to Art. 17(1) and (4) of Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC ("**MAR Regulation**"), The Management Board of Gi Group Poland S.A. ("**Issuer**" or "**Company**"), communicates the confidential information, the public disclosure of which was delayed by the Company on 9 June 2021 pursuant to Art. 17(4) of the MAR Regulation, with the following wording.

The Management Board of the Company informs about an application made on 9 June 2021 to the Issuer's lending Banks ("**Banks**") for consent to the sale of its quota share in the Issuer's subsidiary, i.e. Prohumán 2004 Kft. ("**Prohuman**") (constituting 80.22% of the total share capital of Prohuman) ("**Transaction**"), under pre-determined conditions:

- (i) the selling price will be between PLN 145,000,000 and PLN 150,000,000 (the "**Price**");
- (ii) the existing debts of the Company towards Prohuman will be cancelled by Prohuman, which will occur simultaneously with the transfer by the Company to the buyer of Prohuman shares under the Transaction;
- (iii) the Price will be the net purchase price of all Prohuman share held by the Company; and
- (iv) if the Transaction is finalized on the terms pre-determined, the Banks will release the pledge, governed by Hungarian law, established in favor of the Banks on all the Issuer's shares in Prohuman in order to secure the Banks' claims.

If the negotiations are successful, the Issuer will immediately publish information about it in the form of an appropriate current report.

As a result of the analysis carried out, the Issuer assumed that qualification of the above-mentioned information as confidential within the meaning of Art. 17 (1) MAR, subject to publication in the form of this report, is justified.

**Legal basis:**

Art. 17(1) and (4) of MAR (Regulation EU No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC.

**Signatures:**

Iwona Szmitkowska – President of the Management Board

Nicola Dell'Edera - Vice-President of the Management Board